Amicus Therapeutics Inc. (FOLD)
NASDAQ: FOLD
· Real-Time Price · USD
6.05
0.02 (0.33%)
At close: Jun 16, 2025, 3:59 PM
6.05
-0.08%
After-hours: Jun 16, 2025, 04:04 PM EDT
0.33% (1D)
| Bid | 5.96 |
| Market Cap | 1.86B |
| Revenue (ttm) | 543.14M |
| Net Income (ttm) | -29.37M |
| EPS (ttm) | -0.09 |
| PE Ratio (ttm) | -67.28 |
| Forward PE | 23.77 |
| Analyst | Buy |
| Ask | 6.23 |
| Volume | 5,921,932 |
| Avg. Volume (20D) | 4,418,703 |
| Open | 6.07 |
| Previous Close | 6.03 |
| Day's Range | 5.89 - 6.15 |
| 52-Week Range | 5.81 - 12.65 |
| Beta | 0.53 |
About FOLD
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol FOLD
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for FOLD stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
-13.02%
Amicus Therapeutics shares are trading lower after...
Unlock content with
Pro Subscription
8 months ago
+14%
Amicus Therapeutics shares are trading higher after the company announced it entered into a license agreement with Teva and resolved its Galafold patent litigation.
4 days ago · seekingalpha.com
Amicus Therapeutics: Opportunity Awaits In This Beaten Down PharmaAmicus Therapeutics is a commercial-stage biotech with a focused pipeline in Fabry, Pompe, and rare kidney diseases. Galafold, its lead therapy, is the only approved oral treatment for Fabry disease a...
1 month ago · seekingalpha.com
Amicus Therapeutics, Inc. (FOLD) Q1 2025 Earnings Call TranscriptAmicus Therapeutics, Inc. (NASDAQ:FOLD ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Andrew Faughnan - Vice President of Investor Relations Bradley Campbell - Presiden...
